Pleural space diseases are a significant cause of morbidity in the United States with a reported 25% mortality rate within a year of diagnosis. Pleural space diseases, including intrapleural infections, retained hemothorax (RH), and malignant pleural effusions (MPE), often indicate advanced disease. Despite options like video-assisted thoracoscopy (VATS), tube thoracostomy, and intrapleural fibrinolytic therapy (IPFT), treatment remains a significant clinical challenge. IPFT, which describes a combination of administrating tissue plasminogen activator (tPA) and DNase through a chest tube, has shown effectiveness in improving fluid drainage and reducing surgery frequency in a large, randomized control trial and is widely used. However, the success of IPFT varies based on infection severity, patient health, and treatment timing, with a failure rate around 20-25%. This highlights the need for further research to enhance the therapy’s efficacy, investigating both disease mechanisms and optimizing treatment protocols. This review seeks to provide a comprehensive overview of IPFT, highlighting recent advancements, current trends, and existing research gaps.
LauEPMEshraghiMDootsonK, et al.An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection. ERJ Open Res. 2022;8(1):005902021. doi:10.1183/23120541.00590-2021
2.
PiccoloFPopowiczNWongDLeeYC. Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. J Thorac Dis. 2015;7(6):999-1008. doi:10.3978/j.issn.2072-1439.2015.01.30
3.
KoppurapuVMeenaN. A review of the management of complex para-pneumonic effusion in adults. J Thorac Dis. 2017;9(7):2135-2141. doi:10.21037/jtd.2017.06.21
4.
CharalampidisCYouroukouALazaridisG, et al.Pleura space anatomy. J Thorac Dis. 2015;7(Suppl 1):S27-S32. doi:10.3978/j.issn.2072-1439.2015.01.48
5.
AddalaDNBedawiEORahmanNM. Parapneumonic effusion and empyema. Clin Chest Med. 2021;42(4):637-647. doi:10.1016/j.ccm.2021.08.001
6.
AlegreJSuriñachJMVarelaE, et al.Diagnostic accuracy of pleural fluid polymorphonuclear elastase in the differentiation between pyogenic bacterial infectious and non-infectious pleural effusions. Respiration. 2000;67(4):426-432. doi:10.1159/000029542
7.
ZeilerJIdellSNorwoodSCookA. Hemothorax: a review of the literature. Clin Pulm Med. 2020;27(1):1-12. doi:10.1097/CPM.0000000000000343
8.
PatelNJDultzLLadhaniHA, et al.Management of simple and retained hemothorax: a practice management guideline from the Eastern Association for the Surgery of Trauma. Am J Surg. 2021;221(5):873-884. doi:10.1016/j.amjsurg.2020.11.032
9.
NemetMVasilićMErgelaševSKuhajdaIErgelaševI. Intrapleural fibrinolytic therapy with alteplase for the management of multiloculated malignant pleural effusion: a case series. Cureus. 2022;14(8):e27549. doi:10.7759/cureus.27549
10.
GayenS. Malignant pleural effusion: presentation, diagnosis, and management. Am J Med. 2022;135(10):1188-1192. doi:10.1016/j.amjmed.2022.04.017
11.
SheblEPaulM. Parapneumonic Pleural Effusions and Empyema Thoracis. St. Petersburg, FL: StatPearls; 2024.
12.
McCauleyLDeanN. Pneumonia and empyema: causal, casual or unknown. J Thorac Dis. 2015;7(6):992-998. doi:10.3978/j.issn.2072-1439.2015.04.36
13.
KroegelCAntonyVB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J. 1997;10(10):2411-2418. doi:10.1183/09031936.97.10102411
14.
LightRWMacGregorMIBallWCJrLuchsingerPC. Diagnostic significance of pleural fluid pH and PCO2. Chest. 1973;64(5):591-596. doi:10.1378/chest.64.5.591
15.
HammHLightRW. Parapneumonic effusion and empyema. Eur Respir J. 1997;10(5):1150-1156. doi:10.1183/09031936.97.10051150
16.
ChouYPLinHLWuTC. Video-assisted thoracoscopic surgery for retained hemothorax in blunt chest trauma. Curr Opin Pulm Med. 2015;21(4):393-398. doi:10.1097/MCP.0000000000000173
17.
PsallidasIKalomenidisIPorcelJMRobinsonBWStathopoulosGT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189-198. doi:10.1183/16000617.0019-2016
18.
FerreiroLSuárez-AnteloJÁlvarez-DobañoJMToubesMERiveiroVValdésL. Malignant pleural effusion: diagnosis and management. Canadian Respiratory Journal. 2020;2020:1-11. doi:10.1155/2020/2950751
19.
SkokKHladnikGGrmACrnjacA. Malignant pleural effusion and its current management: a review. Medicina. 2019;55(8):490. doi:10.3390/medicina55080490
20.
BibbyACDornPPsallidasI, et al.ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018;52(1):1800349. doi:10.1183/13993003.00349-2018
21.
LightRWGirardWMJenkinsonSGGeorgeRB. Parapneumonic effusions. Am J Med. 1980;69(4):507-512. doi:10.1016/0002-9343(80)90460-x
LightRW. Pleural effusions. Med Clin North Am. 2011;95(6):1055-1070. doi:10.1016/j.mcna.2011.08.005
24.
ChenKYLiawYSWangHCLuhKTYangPC. Sonographic septation: a useful prognostic indicator of acute thoracic empyema. J Ultrasound Med. 2000;19(12):837-843. doi:10.7863/jum.2000.19.12.837
25.
YangLWangKLiWLiuD. Chest ultrasound is better than CT in identifying septated effusion of patients with pleural disease. Sci Rep. 2024;14(1):11964. doi:10.1038/s41598-024-62807-4
26.
AquinoSLWebbWRGushikenBJ. Pleural exudates and transudates: diagnosis with contrast-enhanced CT. Radiology. 1994;192(3):803-808. doi:10.1148/radiology.192.3.8058951
27.
ChiaoDHanleyMOlazagastiJM. CT volumetric analysis of pleural effusions: a comparison with thoracentesis volumes. Acad Radiol. 2015;22(9):1122-1127. doi:10.1016/j.acra.2015.03.015
28.
ColiceGLCurtisADeslauriersJ, et al.Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest. 2000;118(4):1158-1171. doi:10.1378/chest.118.4.1158
29.
FarjahFSymonsRGKrishnadasanBWoodDEFlumDR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg. 2007;133(2):346-351. doi:10.1016/j.jtcvs.2006.09.038
30.
LightRWNguyenTMulliganMESasseSA. The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung. 2000;178(1):13-18. doi:10.1007/s004080000002
31.
RahmanNMMaskellNAWestA, et al.Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526. doi:10.1056/NEJMoa1012740
32.
CargillTNHassanMCorcoranJP, et al.A systematic review of comorbidities and outcomes of adult patients with pleural infection. Eur Respir J. 2019;54(3):1900541. doi:10.1183/13993003.00541-2019
33.
PopowiczNBintcliffeODe FonsekaD, et al.Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The alteplase dose assessment for pleural infection therapy project. Annals ATS. 2017;14(6):929-936. doi:10.1513/AnnalsATS.201609-673OC
34.
MajidAKheirFFolchA, et al.Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single-center experience. Annals ATS. 2016;13(9):1512-1518. doi:10.1513/AnnalsATS.201602-127OC
35.
ShenKRBribriescoACrabtreeT, et al.The American association for thoracic surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153(6):e129-e146. doi:10.1016/j.jtcvs.2017.01.030
36.
DaviesHEDaviesRJODaviesCWHBTS Pleural Disease Guideline Group. Management of pleural infection in adults: British thoracic society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii41-53. doi:10.1136/thx.2010.137000
37.
ScarciMAbahUSolliP, et al.EACTS expert consensus statement for surgical management of pleural empyema. Eur J Cardiothorac Surg. 2015;48(5):642-653. doi:10.1093/ejcts/ezv272
38.
JandaSSwistonJ. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta-analysis. CHEST. 2012;142(2):401-411. doi:10.1378/chest.11-3071
39.
DennisBMGondekSPGuyerRAHamblinSEGunterOLGuillamondeguiOD. Use of an evidence-based algorithm for patients with traumatic hemothorax reduces need for additional interventions. J Trauma Acute Care Surg. 2017;82(4):728-732. doi:10.1097/TA.0000000000001370
40.
MoweryNTGunterOLCollierBR, et al.Practice management guidelines for management of hemothorax and occult pneumothorax. J Trauma. 2011;70(2):510-518. doi:10.1097/TA.0b013e31820b5c31
41.
HendriksenBSKurokiMTArmenSBReedMFTaylorMDHollenbeakCS. Lytic therapy for retained traumatic hemothorax: a systematic review and meta-analysis. Chest. 2019;155(4):805-815. doi:10.1016/j.chest.2019.01.007
42.
DuBoseJInabaKDemetriadesD, et al.Management of post-traumatic retained hemothorax: a prospective, observational, multicenter AAST study. J Trauma Acute Care Surg. 2012;72(1):11-316. doi:10.1097/TA.0b013e318242e368
43.
MeyerDMJessenMEWaitMAEstreraAS. Early evacuation of traumatic retained hemothoraces using thoracoscopy: a prospective, randomized trial. Ann Thorac Surg. 1997;64(5):1396-1401. doi:10.1016/S0003-4975(97)00899-0
44.
TongBCHannaJTolozaEM, et al.Outcomes of video-assisted thoracoscopic decortication. Ann Thorac Surg. 2010;89(1):220-225. doi:10.1016/j.athoracsur.2009.09.021
45.
KuglerNWCarverTWMiliaDPaulJS. Thoracic irrigation prevents retained hemothorax: a prospective propensity scored analysis. J Trauma Acute Care Surg. 2017;83(6):1136-1141. doi:10.1097/TA.0000000000001700
46.
RobertsMENevilleEBerrisfordRGAntunesGAliNJBTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32-ii40. doi:10.1136/thx.2010.136994
47.
ChanCSekowskiVZhengB, et al.Combination tissue plasminogen activator and DNase for loculated malignant pleural effusions: a single-center retrospective review. J Bronchology Interv Pulmonol. 2023;30(3):238-243. doi:10.1097/lbr.0000000000000871
48.
ChungKCBorregoMEShortJKristofekLBuelowNGelmontDM. Health-related quality of life (HRQOL) in patients with Alpha1-Antitrypsin (AAT) deficiency and effect of augmentation therapy: preliminary results. Chest. 2005;128(4):261S. doi:10.1378/chest.128.2.690
49.
FooCTHerreJ. Ambulatory intrapleural fibrinolytic therapy in highly viscous recurrent malignant pleural effusion. Case Rep Oncol. 2021;14(1):466-469. doi:10.1159/000515077
50.
TilletWSherryS. Effect in patients of streptococcic fibri-nolysin(streptokinase) and streptococcic desoxyribonuclease on fibninous, purulent and sanguineous pleural exudatlons. J Clin Investigation. 1949;28:173.
51.
RosenHNadkarniVTherouxMPadmanRKleinJ. Intrapleural streptokinase as adjunctive treatment for persistent empyema in pediatric patients. Chest. 1993;103(4):1190-1193. doi:10.1378/chest.103.4.1190
52.
MoultonJSMoorePTMenciniRA. Treatment of loculated pleural effusions with transcatheter intracavitary urokinase. AJR Am J Roentgenol. 1989;153(5):941-945. doi:10.2214/ajr.153.5.941
53.
LeeKSImJGKimYHHwangSHBaeWKLeeBH. Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study. Radiology. 1991;179(3):771-775. doi:10.1148/radiology.179.3.2027990
54.
BourosDSchizaSPatsourakisGChalkiadakisGPanagouPSiafakasNM. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med. 1997;155(1):291-295. doi:10.1164/ajrccm.155.1.9001327
55.
BourosDSchizaSTzanakisNChalkiadakisGDrositisJSiafakasN. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med. 1999;159(1):37-42. doi:10.1164/ajrccm.159.1.9803094
56.
DiaconAHTheronJSchuurmansMMVan de WalBWBolligerCT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med. 2004;170(1):49-53. doi:10.1164/rccm.200312-1740OC
57.
MaskellNADaviesCWNunnAJ, et al.U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352(9):865-874. doi:10.1056/NEJMoa042473
58.
SimpsonGRoomesDHeronM. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest. 2000;117(6):1728-1733. doi:10.1378/chest.117.6.1728
59.
ZhuZHawthorneMLGuoY, et al.Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model. Chest. 2006;129(6):1577-1583. doi:10.1378/chest.129.6.1577
60.
WalkerCAShirkMBTschampelMMViscontiJA. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother. 2003;37(3):376-379. doi:10.1345/aph.1C248
61.
BarrettCDMoorePKMooreEE, et al.Neutrophil-mediated inflammatory plasminogen degradation, rather than high plasminogen-activator inhibitor-1, may underly failures and inefficiencies of intrapleural fibrinolysis. Chest. 2024;167:67–75. doi:10.1016/j.chest.2024.04.005
62.
KomissarovAARahmanNLeeYCG, et al.Fibrin turnover and pleural organization: bench to bedside. Am J Physiol Lung Cell Mol Physiol. 2018;314(5):L757-L768. doi:10.1152/ajplung.00501.2017
63.
KwiecinskiJNaMJarnebornA, et al.Tissue plasminogen activator coating on implant surfaces reduces Staphylococcus aureus biofilm formation. Appl Environ Microbiol. 2015;82(1):394-401. doi:10.1128/aem.02803-15
64.
WuKUranoTIharaH, et al.The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood. 1995;86(3):1056-1061.
65.
JørgensenNPZobekNDreierC, et al.Streptokinase treatment reverses biofilm-associated antibiotic resistance in Staphylococcus aureus. Microorganisms. 2016;4(3):36. doi:10.3390/microorganisms4030036
66.
PopowiczNDCarsonCFChakeraAKayIWatererGWLeeYC. Human pleural fluid is a potent growth medium for bacteria especially Streptococcus pneumoniae. Respirology. 2015;20:126.
67.
AkulianJBedawiEOAbbasH, et al.Bleeding risk with combination intrapleural fibrinolytic and enzyme therapy in pleural infection: an international, multicenter, retrospective cohort study. Chest. 2022;162(6):1384-1392. doi:10.1016/j.chest.2022.06.008
68.
BedawiEOKanellakisNICorcoranJP, et al.The biological role of pleural fluid PAI-1 and sonographic septations in pleural infection: analysis of a prospectively collected clinical outcome study. Am J Respir Crit Care Med. 2023;207(6):731-739. doi:10.1164/rccm.202206-1084OC
69.
KomissarovAAFlorovaGAzghaniAO, et al.Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models. Am J Physiol Lung Cell Mol Physiol. 2016;311(2):L389-L399. doi:10.1152/ajplung.00171.2016
70.
BarrettCDMooreHBBanerjeeASillimanCCMooreEEYaffeMB. Human neutrophil elastase mediates fibrinolysis shutdown through competitive degradation of plasminogen and generation of angiostatin. J Trauma Acute Care Surg. 2017;83(6):1053-1061. doi:10.1097/ta.0000000000001685
71.
ShapiroADNakarCParkerJM, et al.Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018;131(12):1301-1310. doi:10.1182/blood-2017-09-806729
72.
IdellSRahmanNM. Intrapleural fibrinolytic therapy for empyema and pleural loculation: knowns and unknowns. Ann Am Thorac Soc. 2018;15(5):515-517. doi:10.1513/AnnalsATS.201711-848PS
